ライフサイエンスコーパス: green monkey

1 estrogen-replaced nonhuman primates (African green monkeys).

2 ces were obtained for cynomolgus macaque and green monkey.

3 rimate species: marmoset, rhesus macaque and green monkey.

4 otype 3 (SFVagm-3), isolated from an African green monkey.

5 g natural SIV variants isolated from African green monkeys.

6 model of lymphatic obstruction using African green monkeys.

7 -3-fold higher in cynomolgus monkeys than in green monkeys.

8 sterol levels were 50% lower than was fed to green monkeys.

9 CAT2 mRNA nor protein was diet-responsive in green monkeys.

10 ary cholesterol, and less responsive African green monkeys.

11 simian immunodeficiency viruses from African green monkeys.

12 tralization titers in RSV-preexposed African green monkeys.

13 vet, grivet, and tantalus species of African green monkeys.

14 nted in the striatum of MPTP-treated African green monkeys.

15 n the dorsal and ventral striatum of African green monkeys.

16 candidates after a single passage in African green monkeys.

17 SARS-CoV-2 using SARS-CoV-2 infected African green monkeys.

18 d suPAR levels and glomerulopathy in African green monkeys.

19 acaques, rhesus macaques, and vervet African green monkeys.

20 immunodeficiency virus infections of African Green Monkeys.

21 both LDL receptor-deficient mice and African green monkeys.

22 DSS treatment of SIV-infected African green monkeys, a natural host species for SIV that does

23 stration to the respiratory tract of African green monkeys, a permissive primate host.

24 uman A3C (hA3C), human A3DE (hA3DE), African green monkey A3F (agmA3F), and rhesus macaque A3F (rhA3F

25 V) Vif was shown to bind and degrade African green monkey A3G (agmA3G) and, unexpectedly, human A3C.

26 re, we report the DNA sequence of an African green monkey AAV integration site isolated from CV-1 cel

27 t rhesus macaque APOBEC3G (rhA3G) or African green monkey (AGM) APOBEC3G (agmA3G) because of a failur

28 for studying HeV infection, with the African green monkey (AGM) appearing to most faithfully reproduc

29 Currently, the African green monkey (AGM) best mimics human henipavirus-induced

30 The present report reveals that African green monkey (AGM) cells, which contain extensive alpha-

31 within human cells that is absent in African green monkey (AGM) cells.

32 EC3G but does not block the mouse or African green monkey (AGM) enzyme.

33 mined the pathogenesis of HeV in the African green monkey (AGM) following intratracheal inoculation.

34 inical studies were conducted in the African green monkey (AGM) inhalational model of pneumonic plagu

35 Here, an African green monkey (AGM) model was used to elucidate immune me

36 his issue, we established a neonatal African green monkey (AGM) nonhuman primate model that could be

37 ctored COVID-19 vaccine CVXGA1 in an African green monkey (AGM) nonhuman primate model.

38 sely, the Vif protein encoded by the African green monkey (agm) simian immunodeficiency virus (SIV) c

39 the A3G-Vif interaction within four African green monkey (AGM) subspecies, which are each naturally

40 ndogenous retroviruses produced from African green monkey (AGM) tissues or cell lines.

41 ved by comparing a natural SIV host, African green monkey (AGM) to an AIDS susceptible species, rhesu

42 n, we isolated cDNA clones of human, African green monkey (AGM), and NIH/Swiss mouse CCR5s, and we qu

43 In a natural host of SIV, the African green monkey (AGM), NK cells mediate a strong control of

44 b from its natural host, the sabaeus African green monkey (AGM), to a new host, the pigtailed macaque

45 investigate replication in primates, African green monkeys (AGM) and rhesus macaques (n = 4) were ino

46 African green monkeys (AGM) and sooty mangabeys (SM) are well-st

47 Natural hosts, such as African green monkeys (AGM) and sooty mangabeys (SM), are protec

48 ection in its natural hosts, such as African green monkeys (AGM) and sooty mangabeys (SM).

49 African green monkeys (AGM) are natural hosts of simian immunode

50 African green monkeys (AGM) are natural hosts of SIV, and infect

51 African green monkeys (AGM) do not develop overt signs of diseas

52 were assessed in naturally infected African green monkeys (AGM) of the vervet subspecies (Chlorocebu

53 In contrast, both marmosets and African green monkeys (AGM) proved susceptible to aerosolized RV

54 genic differences between strains, 4 African green monkeys (AGM) were exposed to NiVM and 4 AGMs were

55 ssive infection (SIVagm infection of African green monkeys (AGM)), and transient, controlled infectio

56 impanzees, sooty mangabeys (SM), and African green monkeys (AGM).

57 range of African primates, including African green monkeys (AGM).

58 daVax to elicit responses in newborn African green monkeys (AGM).

59 inistered by head dome inhalation in African green monkeys (AGM).

60 d within 2-6 hours of fever onset in African green monkeys (AGM).

61 EHO and ALI), and one strain of SIV (African Green Monkey, AGM).

62 rulence in BALB/c mice, ferrets, and African green monkeys (AGMs) (Chlorocebus aethiops).

63 iral pathogens in two populations of African green monkeys (AGMs) (Chlorocebus sabaeus) from Africa a

64 A model was developed in African green monkeys (AGMs) after challenge with a lethal dose

65 such approach to compare T cells of African green monkeys (AGMs) and rhesus macaques (RMs).

66 nd in nonpathogenic SIV infection of African green monkeys (AGMs) and sooty mangabeys.

67 African green monkeys (AGMs) are a natural host of SIV that do n

68 geographically dispersed species of African green monkeys (AGMs) are all infected with highly divers

69 African green monkeys (AGMs) are natural hosts of simian immunod

70 African green monkeys (AGMs) are natural primate hosts of simian

71 African green monkeys (AGMs) are naturally infected with a simia

72 African green monkeys (AGMs) are naturally infected with simian

73 We used African green monkeys (AGMs) as a nonhuman primate (NHP) model f

74 the findings in humans and evaluated African green monkeys (AGMs) as a nonhuman primate model.

75 roximately 98-99% identical) CCR5 of African green monkeys (AGMs) avidly binds beta-chemokines and fu

76 est the hypothesis that SIV-infected African green monkeys (AGMs) avoid AIDS due to virus replication

77 th m102.4 for the ability to protect African green monkeys (AGMs) from a stringent NiV challenge.

78 Chronically SIVagm-infected African green monkeys (AGMs) have a remarkably stable nonpathoge

79 liciting a strong immune response in African green monkeys (AGMs) in a single dose.

80 report two cases of ARDS in two aged African green monkeys (AGMs) infected with SARS-CoV-2 that had p

81 fection in sooty mangabeys (SMs) and African green monkeys (AGMs) is associated with low levels of im

82 of rVSV-DeltaG-NiVBG, we vaccinated African green monkeys (AGMs) one year before challenge with an u

83 Chronically SIV-infected African Green Monkeys (AGMs) partially recover mucosal CD4(+) T-

84 s of chronically SIV-infected sabeus African green monkeys (AGMs) revealed that gastrointestinal memo

85 We show that African green monkeys (AGMs) support robust SARS-CoV-2 replicati

86 d from pigtailed macaques (PTMs) and African green monkeys (AGMs) that experience different SIVsab in

87 d SIVsab from the sabaeus species of African green monkeys (AGMs) to pigtailed macaques (PTMs).

88 iV delivered by the aerosol route in African green monkeys (AGMs) used the Malaysia strain (NiVM), wh

89 p of 10 rhesus macaques (RMs) and 10 African green monkeys (AGMs) was exposed to aerosolized B. pseud

90 Caribbean-born African green monkeys (AGMs) were classified as Chlorocebus saba

91 ans from chronically SIVagm-infected African green monkeys (AGMs) were frequently CXCR5(+) and entere

92 A small number of African green monkeys (AGMs) were introduced into the Caribbean

93 the respiratory tracts of hamsters, African green monkeys (AGMs), and chimpanzees.

94 dominantly in sooty mangabeys (SMs), African green monkeys (AGMs), and mandrills.

95 dominantly in sooty mangabeys (SMs), African green monkeys (AGMs), and mandrills.

96 African green monkeys (AGMs), Chlorocebus pygerythrus, are a nat

97 n immunodeficiency virus SIVagm from African green monkeys (AGMs), do not encode Vpu.

98 In African green monkeys (AGMs), rHPIV1-P(C-) was considerably more

99 eficiency virus (SIV) hosts, such as African green monkeys (AGMs), sustain nonpathogenic SIV infectio

100 Unlike HIV-1-infected humans, African green monkeys (AGMs), the natural SIV host species, sust

101 and uninfected natural hosts of SIV, African green monkeys (AGMs), to that of RMs.

102 and attenuated in mice, ferrets, and African green monkeys (AGMs).

103 te and chronic SIVagm replication in African green monkeys (AGMs).

104 didate vaccine was used to vaccinate African green monkeys (AGMs).

105 al days, in the respiratory tract of African green monkeys (AGMs).

106 ns were tested for immunogenicity in African green monkeys (AGMs).

107 ment on lung CYP2A protein levels in African green monkeys (AGMs).

108 uction and replicated efficiently in African green monkeys (AGMs).

109 African green monkeys (AGMs; genus Chlorocebus) are a natural ho

110 caques [PTMs]) and nonpathogenic (in African green monkeys [AGMs]) SIVsab infections to assess the si

111 OROV also replicated in sabeus African green monkey, albeit at lower levels than other hosts.

112 lizing antibody titers obtained from African green monkeys and after human vaccination and natural in

113 strate that nonhuman primates (NHPs; African green monkeys and cynomolgus macaques) harbor serosal B

114 tified multiple SAMHD1 haplotypes in African Green Monkeys and find that the vpr gene from different

115 hosts (for example, sooty mangabeys, African green monkeys and mandrills) share many features of HIV

116 s used to disrupt CypA in cells from African green monkeys and rhesus macaques.

117 ts and cholesterol to nonpathogenic (African green monkeys) and pathogenic (pigtailed macaques) SIV h

118 utcomes of SIVsab infection in PTMs, African green monkeys, and rhesus macaques are different, the us

119 ciently in the respiratory tracts of African green monkeys, and the infected animals developed a high

120 TRIM5alpha B30.2 domain v1 region of African green monkeys are also associated with broader antiretro

121 ic infections in natural hosts, such African green monkeys, are characterized by a lack of gut microb

122 iency virus (SIVagm) Vif can inhibit African green monkey but not human Apo3G.

123 administered separately to groups of African green monkeys by the intranasal/intratracheal route.

124 African green monkeys can maintain long-term persistent infectio

125 Similar results were observed in the African green monkey cell line COS7.

126 ng activities expressed by human and African green monkey cell lines.

127 le directed secretion of both Ags in African green monkey cells and functioned as an adjuvant for MHC

128 pr proteins are capable of arresting African green monkey cells but are completely inactive in human

129 chia coli and as a secreted protein from Cos green monkey cells was also investigated.

130 (RhTRS1) fulfills these functions in African green monkey cells, but not rhesus or human cells.

131 In African green monkey cells, HIV-1 virus-like particles ablate re

132 IgA did not inhibit HAV infection of African green monkey cells, suggesting that the IgA and the viru

133 n after entry into rhesus macaque or African green monkey cells, where, paradoxically, the interactio

134 e Lv1 activity in rhesus macaque and African green monkey cells.

135 ity could be demonstrated in cognate African green monkey cells.

136 African green monkeys (Cercopithecus aethiops sabaeus) were ovar

137 Four African green monkeys (Cercopithecus aethiops) were injected sub

138 s musculus), hamster (Mesocricetus auratus), green monkey (Ceropithecus aethiops) and human (Homo sap

139 Herein we report that two species of African green monkeys (Chlorocebus sabaeus and C. pygerythrus) i

140 cyte-depleting antibodies to sabaeus African green monkeys (Chlorocebus sabaeus) before challenge wit

141 herpesviruses recently identified in African green monkeys, Chlorocebus rhadinovirus types 1 and 2 (C

142 An African green monkey CMV UL32 homolog complemented DeltaUL32-BAC

143 d a range of restriction in mice and African green monkeys comparable with that of two attenuated RSV

144 duction in LNCaP cells as well as in African green monkey CV-1 cells.

145 Infection of African green monkey CV1 cells with SV40 resulted in the activat

146 nd in vivo studies in cynomolgus and African Green monkeys demonstrated a >10-fold higher lung tissue

147 rom chimpanzees] and SIVagmSab [from African green monkeys]) discordantly in different regions of the

148 nts from humans, rhesus monkeys, and African green monkeys displayed different but overlapping restri

149 e show that many CD4(+) T cells from African green monkeys downregulate CD4 in vivo as they enter the

150 We have collected the brains of African green monkeys during multiple Nipah virus, Bangladesh st

151 ery atherosclerosis were examined in African green monkeys fed diets containing cholesterol and 35% o

152 We immunised eight African green monkeys, four with a single dose of BHPIV3/ SARS-S

153 128, previously shown to distinguish African green monkey from human APOBEC3G.

154 y shown that intranasal SV protected African green monkeys from challenge with the related human para

155 r and humoral immunity that protects African green monkeys from SARS-CoV-2 challenge.

156 ruses (family Arteriviridae) in wild African green monkeys from Zambia (malbroucks [Chlorocebus cynos

157 Here, we discover two new viruses in African green monkeys from Zambia and South Africa.

158 African green monkeys (genus Chlorocebus) can be infected with s

159 In African green monkeys immunized intranasally and intratracheally

160 African green monkeys immunized through the respiratory tract wi

161 African green monkeys immunized with b/h PIV3 expressing either

162 uated the immunological responses of African green monkeys immunized with multiple F and G protein-ba

163 African green monkeys immunized with two doses of the vector exp

164 NDV-HA was administered to African green monkeys in two doses of 2 x 10(7) infectious units

165 The lesions seen in the brain of African green monkeys infected with Nipah virus, Bangladesh were

166 d/nonprogressive infection) and from African green monkeys infected with SIVsab9315BR (nonpathogenic

167 SARS-CoV-2 antiviral efficacy in an African green monkey infection model.

168 We compared African green monkeys inoculated with infectious SARS-CoV-2 or i

169 set of clinical anthrax disease, the African green monkey is a suitable animal model exhibiting a dis

170 e expression (~2 log orders) for the African green monkey isolate AAV4.

171 enuated viruses adapted to growth in African green monkey kidney (AGMK) and MRC-5 cells, respectively

172 natural function which serves as an African green monkey kidney (AGMK) cell receptor for HAV.

173 Serum-starved primary African green monkey kidney (AGMK) cells also showed decreased p

174 ntibodies raised against susceptible African green monkey kidney (AGMK) cells as probes.

175 ed from a cDNA expression library of African green monkey kidney (AGMK) cells by using protective mon

176 Hepatitis A virus (HAV) infects African green monkey kidney (AGMK) cells via the HAV cellular re

177 ar receptor 1 (havcr-1) and protects African green monkey kidney (AGMK) clone GL37 cells (GL37 cells)

178 Buffalo green monkey kidney (BGMK) cells expressing human DAF (B

179 sackievirus B6 replication in living Buffalo green monkey kidney (BGMK) cells via Tat peptide deliver

180 To characterize interactions between African green monkey kidney (BS-C-1) cell proteins and the predi

181 M175/P16, enhance growth in cultured African green monkey kidney (BS-C-1) cells but not in fetal rhes

182 Lytic infection of African green monkey kidney (CV-1) cells by simian virus 40 (SV4

183 and establishing stably transfected African green monkey kidney (CV1) cell lines expressing reporter

184 We found that the infection of African green monkey kidney (Vero) cells by vesicular stomatitis

185 , and produced very small plaques on African green monkey kidney (Vero) cells that were similar in si

186 ding porcine kidney (PK15) cells and African green monkey kidney (Vero) cells, was inhibited by noncy

187 N2, H5N1 and H7N9 vaccine viruses in African green monkey kidney and Madin-Darby canine kidney cells.

188 ibited vaccinia virus replication in African green monkey kidney BSC-40 cells.

189 s and deletions were monitored in an African green monkey kidney cell culture system (COS-7 cells) as

190 reliminary studies indicated that an African green monkey kidney cell line (Vero) is a suitable syste

191 epithelial cell line (Calu-3) and an African green monkey kidney cell line (Vero-E6).

192 The selectivity was demonstrated in a green monkey kidney cell line, CV-1, in which CITCO disp

193 rescue and growth properties in the African green monkey kidney cell line, Vero.

194 within a few cycles of infection in African green monkey kidney cell lines CV-1, CV-1P, TC-7, MA-134

195 generates H2O2, was introduced into African green monkey kidney cells (CV-1 cells) under the control

196 ell homeostasis were investigated in African green monkey kidney cells (CV-1) by assessing the appear

197 1.3, was heterologously expressed in African Green Monkey kidney cells (CV-1) using a vaccinia virus/

198 n U937 cells (histiocytic lymphoma), African green monkey kidney cells (MARC-145 and Vero), primary m

199 y of HSV-1 derived from immortalized African green monkey kidney cells (Vero), immortalized human ker

200 e microsurgically removed from BSC-1 African green monkey kidney cells before the completion of S pha

201 African green monkey kidney cells expressing pIgR demonstrated H

202 Hepatitis A virus (HAV) infects African green monkey kidney cells via HAV cellular receptor 1 (h

203 2D cell culture infection model with Buffalo Green Monkey kidney cells was employed and infection wit

204 wing passage in C6/36 cells, primary African green monkey kidney cells, or Vero cells.

205 African green monkey kidney cells, Vero C1008, polarizable epith

206 lanoma cell line but not to the CV-1 African green monkey kidney cells, which express CD44 at low lev

207 dney, A549, rhabdomyosarcoma, and/or Buffalo green monkey kidney cells.

208 pendent viral translation in vivo in African green monkey kidney cells.

209 ent in SARS-CoV-2-infected controls (African green monkey kidney clone E6 [Vero E6] cultures).

210 cells and CYP1A1- and AHR-deficient African green monkey kidney CV-1 cells.

211 Cytotoxicity was evaluated in green monkey kidney epithelial (Vero) cells and MT-4 leu

212 eir respective intracellular niches, African green monkey kidney epithelial (Vero) cells, A/J mouse b

213 tion was detected in only six: three African green monkey kidney epithelial cell lines (Vero, Vero E6

214 0 DNA replication in infected BSC-1 (African green monkey kidney epithelial) cells, albeit at a great

215 ve in 293T (embryonic kidney), Vero (African-green monkey kidney epithelial), 3T12 (mouse fibroblast)

216 interact with CD66a-transfected COS (African green monkey kidney) and CHO (Chinese hamster ovary) cel

217 COS7 (African Green Monkey kidney) cells stably transfected with the m

218 Using COS (African green monkey kidney) cells transfected with cDNAs encodi

219 o cells, which were derived from the African green monkey kidney, represent one of the few mammalian

220 These data demonstrate that African green monkey-like natural killer cell differentiation pr

221 CAT2 gene product was cloned from an African green monkey liver cDNA library.

222 In cynomolgus monkeys but not in green monkeys, liver free cholesterol concentrations wer

223 ferent species of naturally infected African green monkeys living in different regions across Africa.

224 , complete suppression of macaque or African green monkey Lv1 was achieved by the additive effect of

225 CXCR6 by SIVagmSab to infect sabaeus African green monkey lymphocytes.

226 natural SIV hosts (sooty mangabeys, African green monkeys, mandrills, sun-tailed monkeys, and chimpa

227 Eleven fetal African green monkey midbrains were immunostained for tyrosine h

228 ogether, these data suggest that the African green monkey model exhibits important similarities to hu

229 e01693-23, 2024, ) in an established African green monkey model of disease.

230 ed the use of RSV (Memphis 37) in an African green monkey model of intranasal infection and identifie

231 IV5/G) protein in the cotton rat and African green monkey models for their replication, immunogenicit

232 pliced exon 10 were identical between human, green monkey, mouse, rat, and pig, while 207 consecutive

233 Adult African green monkeys naturally have low numbers of CD4 T cells

234 mbinant viruses were administered to African green monkeys (NDV-BC and NDV-LS) and rhesus monkeys (ND

235 The infecting SFV originated from an African green monkey (one person) and baboons (three people).

236 African green monkeys, one natural host species, avoid simian AI

237 e describe a genome reference of the African green monkey or vervet (Chlorocebus aethiops).

238 es from a human infected with SFV of African green monkey origin (SFV-3).

239 n of endogenous CRF1 in COS-7 cells (African green monkey origin).

240 tion, RhTRS1 binds to phosphorylated African green monkey PKR.

241 adapted to the polymorphisms of the African Green Monkey population in which it is found.

242 haracterized in plasma from infected African Green monkeys, rabbits, and guinea pigs.

243 Hamsters and African green monkeys received a primary intranasal infection wi

244 Four adult St. Kitts green monkeys received embryonic VM grafts into the rost

245 tion and deletion analysis in BSC-1 (African green monkey, renal epithelial) cells revealed that the

246 Finally, in African green monkeys, renal cortical NOS1B expression increased

247 cells or established cell lines from African green monkey, rhesus macaque, and baboon.

248 s after intravenous inoculation into African green monkeys, rhesus monkeys, and marmosets.

249 In an African green monkey RSV infection model, once-daily oral ODV do

250 0 mg/kg IV administration of 1 in an African Green monkey RSV model demonstrated a >2-log(10) reducti

251 ; the human and, to a low level, the African green monkey sequences bound soluble HCV E2 (sE2) and in

252 eavage-efficient mutant, R-R-R-R, in African green monkeys showed that there was no detectable change

253 Both Vif proteins of HIV-1 and African green monkey simian immunodeficiency virus (SIVagm) bind

254 We now report a novel function of African green monkey simian immunodeficiency virus (SIVagm) Vif

255 only human Apo3G (hApo3G), whereas, African green monkey simian immunodeficiency virus (SIVagm) Vif

256 ian immunodeficiency virus SIV(SM)), African green monkey (SIV(AGM)), and Sykes' monkey (SIV(SYK)) is

257 munodeficiency viruses isolated from African green monkeys (SIVagm) contain a single accessory gene h

258 odeficiency virus (SIV) that infects African green monkeys (SIVagm) contains a vpr homologue, which e

259 Simian immunodeficiency virus from African green monkeys (SIVagm) results in asymptomatic infection

260 onpathogenic infection with SIV from African green monkeys (SIVagm), follicles remain generally virus

261 d simian immunodeficiency virus from African green monkeys (SIVagm), in one round of viral replicatio

262 infects rhesus macaques (SIVmac) and African green monkeys (SIVagm).

263 and simian immunodeficiency virus of African green monkeys (SIVagm).

264 itself, HIV-2 and SIV isolated from African green monkeys (SIVAGM).

265 (simian immunodeficiency virus from African green monkeys [SIVagm] and Rhesus macaques [SIVmac]), th

266 d infection by SIVmac and the SIV of African green monkeys, SIVagm.

267 apped mangabey (SIVrcm), the sabaeus African green monkey (SIVagmSAB), and the chimpanzee (SIVcpz) an

268 odeficiency virus (SIV) that infects African green monkeys (SIVagmTAN), unlike human Apobec3DE, which

269 tion in its sabaeus monkey host, the African green monkey species endemic to West Africa.

270 ne into a demyelinated lesion of the African green monkey spinal cord.

271 developed to measure SIVagm from two African green monkey subspecies demonstrated high levels of SIV

272 ed with that previously observed for African green monkeys, suggesting that the HAE model has potenti

273 African green monkeys systemically immunized with HPV-11 VLPs ex

274 D4(+) T cells of young mandrills and African green monkeys than on those of adults, we propose that l

275 SV neutralization antibody titers in African green monkeys that had been infected previously.

276 In African green monkeys that received a primary infection with RSV

277 Here we show in African green monkeys that systemic delivery of an anti-miRNA ol

278 activities were measured in rat and African green monkey tissues.

279 or NiV infection, we exposed 6 adult African green monkeys to a large-particle (approximately 12 mum)

280 In this study, we exposed African green monkeys to B. anthracis spores; examined clinical

281 e compared the plasma virome of West African green monkeys to that in their descendants after importa

282 Sixteen St. Kitts African green monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tet

283 Previously, we have shown that African green monkey TRIM5alpha (AgmTRIM5alpha) potently restric

284 We created a panel of African green monkey TRIM5alpha (TRIM5alpha(AGM)) mutants, many

285 east two different retroviruses, and African green monkey TRIM5alpha was able to inhibit infection by

286 Adult female African green monkeys underwent right C5/6 lateral hemisection w

287 In African green monkeys, vaccine-induced serum and mucosal antibod

288 uman foreskin fibroblasts but not in African green monkey (Vero) cells.

289 A wild-type virus (using African green monkey VeroE6 cells), a pseudovirus (using human C

290 s in one eye of juvenile rhesus macaques and green monkeys, we combined cDNA subtractions, microarray

291 It was found that all vaccinated African green monkeys were completely protected against subseque

292 HMPV-infected chimpanzees and African green monkeys were highly protected from challenge with

293 er respiratory tract of RSV-infected African green monkeys when administered once daily via intratrac

294 otective efficacy in cotton rats and African green monkeys, which are among the best available animal

295 HAV) was originally isolated from an African green monkey with hepatitis and appears to represent a t

296 4 tissue samples from a NiV-infected African green monkey with viral loads as low as 52 genome copies

297 ore natural NHP model, we challenged African green monkeys with the Bangladesh strain of NiV by the i

298 We infected 35 Asian macaques and African green monkeys with viruses that do or do not express Vpx